AZ Outlines COVID-19 Plans With Strong Q2 Update
UK Pharma Is Advancing Two MAbs Into COVID-19 Trials
Executive Summary
AstraZeneca used its robust Q2 update to express hopes that Phase III data from of its COVID-19 vaccine candidate this year could provide it with a regulatory pathway. It is also entering a mAb combination into the clinic as a promising approach against COVID-19.
You may also be interested in...
J.P. Morgan Extras: Pandemic Impact on Launch, Production, Development And More
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
FDA Approves Guardant’s Guardant360 CDX Comprehensive Genomic Profile
The liquid-biopsy test is also a companion diagnostic for osimertinib, AstraZeneca’s drug for non-small cell lung cancer.
AZ Q2 Preview: Pipeline, COVID-19 and M&A Key Focus
AstraZeneca’s half-year results, out on 30 July, will be keenly watched due to the pharma’s attractive near-term growth, pipeline catalysts and its promising COVID-19 vaccine.